{
    "clinical_study": {
        "@rank": "23455", 
        "acronym": "DexCardiac", 
        "arm_group": [
            {
                "arm_group_label": "Dexmedetomidine", 
                "arm_group_type": "Active Comparator", 
                "description": "Dexmedetomidine infusion, without a bolus dose, (or a comparable volume of placebo) will be initiated before the surgical incision at a rate of 0.1 kg/hr; at the end of bypass, the dose will be increased to 0.2 kg/hr."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery"
        }, 
        "brief_title": "Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Disease", 
        "condition_browse": {
            "mesh_term": "Heart Diseases"
        }, 
        "detailed_description": {
            "textblock": "The investigator goal is to evaluate the effects of intraoperative and postoperative\n      dexmedetomidine sedation (versus placebo after cardiac surgery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. 18-85 years old;\n\n          2. Scheduled for cardiac surgery with bypass  (CABG, valve, or combined);\n\n          3. Able to provide a written informed consent;\n\n          4. Hemodynamically stable (heart rate>= 55).\n\n        Exclusion Criteria:\n\n          1. Sick sinus syndrome or Wolff-Parkinson-White syndrome\n\n          2. Atrio-ventricular block\n\n          3. Hypersensitivity or known allergy to dexmedetomidine\n\n          4. Hepatic disease, e.g. twice the normal level of liver enzymes\n\n          5. AF within 1 preoperative month;\n\n          6. Permanent pacemaker;\n\n          7. Use of amiodarone or dexmedetomidine within the last 30 days;\n\n          8. Patients with an ejection fraction under 30% or who had severe heart     failure\n\n          9. Myocardial infarction in the previ\u00acous 7 days;\n\n         10. Body mass index =< 40 (BMI= mass (kg) / height (m)2);\n\n         11. Those tak\u00acing clonidine within last 48 hours."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "965", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02004613", 
            "org_study_id": "12-1379"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dexmedetomidine", 
                "description": "Dexmedetomidine", 
                "intervention_name": "Dexmedetomidine", 
                "intervention_type": "Drug", 
                "other_name": "Dexmedetomidine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Normal saline administration matching dexmedetomidine rate of infusion", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Dexmedetomidine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 3, 2014", 
        "location": {
            "contact": {
                "email": "Johnsor13@ccf.org", 
                "last_name": "Roberta Johnson", 
                "phone": "216-444-9950"
            }, 
            "facility": {
                "address": {
                    "city": "Cleveland", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "44195"
                }, 
                "name": "Cleveland Clinic Main"
            }, 
            "investigator": [
                {
                    "last_name": "Alparslan Turan, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sabry Ayad, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery", 
        "overall_contact": {
            "email": "johnsor13@ccf.org", 
            "last_name": "Roberta Johnson", 
            "phone": "216-444-9950"
        }, 
        "overall_official": {
            "affiliation": "Staff member", 
            "last_name": "Alparslan Turan, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To measure whether dexmedetomidine sedation decreases the incidence of atrial arrhythmias.", 
            "measure": "Sedation Outcome of patients assigned to dexmedetomidine or placebo.", 
            "safety_issue": "Yes", 
            "time_frame": "3 to 90 Days after surgery"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02004613"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The Cleveland Clinic", 
            "investigator_full_name": "Alparslan Turan", 
            "investigator_title": "Staff", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To measure whether dexmedetomidine sedation reduces postoperative delirium.", 
            "measure": "Sedation Outcome of patients assigned to dexmedetomidine or placebo", 
            "safety_issue": "No", 
            "time_frame": "3 to 90 days after surgery"
        }, 
        "source": "The Cleveland Clinic", 
        "sponsors": {
            "collaborator": {
                "agency": "Hospira, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "The Cleveland Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}